Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opinion & Analysis ArQule Inc. ARQL

Arqule Inc is a biopharmaceutical company, engaged in the research and development of therapeutics to treat cancers and rare diseases. The objective of the company is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of the patients. These drugs focus on the biological pathways implicated in a range... see more

Opinion & Analysis (NDAQ:ARQL)

    ArQule Shares Double on Proposed $2.7 Billion Tender Offer from Merck

    Streetwise Reports December 10, 2019

    Price Target Raised on Biopharma Ahead of Leukemia Trial Update

    Streetwise Reports May 9, 2019

    2017 Small-Cap Biotech Watchlist update: up 21% at the end of Q2/17

    The Life Sciences Report July 14, 2017

    2017 Small-Cap biotech watchlist update: holding steady in a volatile market

    The Life Sciences Report April 21, 2017

    2017 Small-Cap Biotech Watchlist: takeaways for investors

    The Life Sciences Report January 19, 2017